ARTICLE | Company News
FDA to discuss Cornerstone's lixivaptan
July 25, 2012 1:52 AM UTC
FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Sept. 13 to discuss an NDA from Cornerstone Therapeutics Inc. (NASDAQ:CRTX) for lixivaptan to treat symptomatic hypervolemic hypona...